Clinical Trial Update: Expanded Access Program for CT1812 (Zervimesine)

View source ↗

Summary

Expanded Access Program update for Cognition Therapeutics' CT1812 (Zervimesine) in dementia with Lewy bodies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia with Lewy Bodies

Drugs mentioned

• Zervimesine (CT1812)

Snippet

Sponsor: Cognition Therapeutics | Conditions: Dementia With Lewy Bodies | Status: NO_LONGER_AVAILABLE